tirzepatide obstructive sleep apnea in Obesity-Related Apnea: Beyond Weight Loss Toward Disease Modification? Medscape | The FDA approved

Most cite the high costs and unclear long-term cost-effectiveness for insurers as reasons for denying coverage

The switch makes sense if you haven't achieved adequate weight loss with Contrave or if you develop diabetes and could benefit from Mounjaro's dual action

Who Qualifies Standard eligibility for semaglutide-based weight loss treatment follows the criteria used in clinical trials and FDA labeling: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia

Xie, Y et al Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation BMJ Medicine, March 18, 2026

A faster transfer (PayID or Osko) gets things moving sooner